Emerging Stocks Down Under 7 June 2022: Polynovo (ASX:PNV)

Polynovo
Polynovo: The pandemic has only delayed its dreams, not ended them
Capped at over $820m and up nearly 500% in five years, Polynovo (ASX: PNV) has been one of the ASX’s most prominent Biotechs. Its NovoSorb technology has been commercialised but has barely reached its full potential. Polynovo’s path has not been without setbacks and investors have punished the company in the past year. But if market conditions return to normal, we believe there is a significant opportunity for the company to capture. Click here to read the previous edition of Emerging Stocks Down Under published 31 May 2022 For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.
Please register or upgrade your plan to access this content.

Save $$$
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$69
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$59
BILLED ANNUALLY
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks